Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

690 Features
BAFF & APRIL: Emerging Targets for Autoimmune & Cancer Therapeutics

18 Jan 06

In 1999 Human Genome Sciences researchers published a study in the journal Science describing a new member of the TNF super-family which they named BLyS. Since that time our understanding of this protein, also known as BAFF, and its homologue APRIL has progressed rapidly. The BAFF sub-family has emerged as a candidate target for therapies of various autoimmune diseases and hematological cancers with breathtaking speed.
LeadDiscovery

Ferriprox prevents heart failure deaths in thalassaemia

16 Jan 06

A new study shows the oral iron-chelator Ferriprox (deferiprone) prevents patients with thalassaemia experiencing heart complications and dying of heart failure. Patients with the condition require frequent blood transfusions with the unwanted effect of excess iron that can build up in organs and endocrine glands. Iron overload in the heart can produce fatal complications so effective treatment with iron chelation therapy to remove iron is vital. The finding that an oral treatment achieves bett
Olwen Glynn Owen - PharmiWeb Field Reporter

2006 –Near Term Expectations for Clinical Research

11 Jan 06

There is little mystery about what the next few years hold for the clinical research industry –it comes down to one word: speed. It is all about speed. The gauntlet has been thrown down and the companies that are able to demonstrate an effective and consistent approach to truncating the timeline of clinical trials will be very successful.
Brian S. Robinson

The Rough Guide to Electronic Data Capture

11 Jan 06

Electronic Data Capture (EDC), three little words that can divide the clinical research community like few others. To some, EDC is a panacea for all the troubles and rising costs of the clinical development process, whilst to others it spells broken promises, and forms the butt of many less than flattering anecdotes.
Andrew Salomon

Charity = Free Job Postings!

11 Jan 06

Free Job Postings for UK Charity Organisations in the Healthcare Sector.
Mike Wood

Blog your Jobs

10 Jan 06

New Blog for Jobs
Mike Wood

Rapid testing vital in tackling Bird Flu

04 Jan 06

Dr Adam Meijer of the Netherlands-based European Influenza Surveillance Scheme (EISS)§ has highlighted the vital role rapid testing must play in combating the global threat of bird flu. Dr Meijer makes his observations in the January issue of Expert Review of Molecular Diagnostics.
Simon Boisseau

Exjade - first oral treatment for iron overload - will make life easier for patients needing regular blood transfusion

22 Dec 05

New data presented at the American Society of Hematology meeting in Atlanta this month suggest the problems associated with iron overload in frequently-transfused patients can now be managed simply with an oral treatment rather than continuous infusions of several hours duration.
Olwen Glynn Owen PharmiWeb Field Reporter

Glivec improves long-term survival prospects for chronic myeloid leukaemia patients

21 Dec 05

Most patients who develop chronic myeloid leukaemia (CML) can now expect to live more than 20 years from diagnosis if they are treated with the tyrosine kinase inhibitor (TKI) Glivec (imatinib) according to haematologists involved in the IRIS (International Randomized Interferon versus STI571) study. Before availability of current treatments, median survival from diagnosis was 3.5 years.
Olwen Glynn Owen - PharmiWeb Field Reporter

Assessing the Top Four Cancer Markets

14 Dec 05

Together, the four major cancer markets, which include colorectal, prostate, lung and breast cancer, were valued at well over $16 billion in 2005, which was an increase of 14 percent in value since 2004. Driving this growth are innovative new products, line extensions for existing products, and the coming of age of the biotech industry.
Arrowhead Publishers

Dronedarone, a new anti-arrhythmic drug in development, may fill unmet need in atrial fibrillation

30 Nov 05

Dronedarone, a new Class III multi-channel blocking anti-arrhythmic drug currently in Phase III development by Sanofi-Aventis for the prevention of atrial fibrillation (AF) and atrial flutter (AFL) may help fill the unmet need for a safe pharmacologic treatment that effectively controls atrial fibrillation, cardiologists said this month. Sanofi-Aventis presented new data on dronedarone at the American Heart Association’s (AHA) annual scientific sessions held in Dallas.
Olwen Glynn Owen - PharmiWeb Field Reporter

HIV doctors underestimate patients’ willingness to use injectables

30 Nov 05

Patients who could benefit from injectable therapies are a lot less needle-phobic than doctors assume, according to research conducted by pharmacist and behavioural scientist Professor Robert Horne. The “Open Mind” study presented at the 10th European AIDS Conference/EACS in Dublin showed over three quarters of patients would be willing to accept self-administered subcutaneous injectable therapy if offered.
Olwen Glynn Owen - PharmiWeb Field Reporter

How to | Enter the cyberspace recruitment market

22 Nov 05

Caution: Your CV is your personal data. My advice as a recruiter, with many years experience in the clinical research industry, would be to take care where you send your CV and make sure your data is treated with the respect it deserves! The important thing is to be selective.
Linda Eden-Ellis

Executive Jobs

11 Nov 05

Due to demand, we at PharmiWeb have added a new Executive Jobs Listing to our comprehensive careers section. All these jobs include packages of over £100K (GBP) per year.
Mike Wood

Pharmaceutical Abbreviations

31 Oct 05

For those new to the industry, a quick round up of the common abbreviations and what they stand for might be useful....
Spencer Marsh

Would you like a chance to win £25!

24 Oct 05

Complete our user survey and you could win a £25 Amazon voucher!
Mike Wood

Diabetes

13 Oct 05

The prevalence of diabetes, in particular type 2 diabetes, is increasing worldwide. Type 2 diabetes increases with age, but recently has been affecting much younger individuals. In the UK, diabetes prevalence has doubled over the last 12-15 years, and is set to double again over a similar timeframe. The prevalence of diabetes in the UK is now, on average, 3.3%, though many patients are undiagnosed.
CSF Medical

PharmiWeb Solutions and Microsoft host unique seminar...and plan next one!

29 Sep 05

On Wednesday 22nd June, PharmiWeb Solutions and Microsoft brought together a senior group of sales and marketing professionals, to discuss how software and e-business based solutions can deliver competitive advantage for the pharmaceutical organisation.
Colin Williams

PharmaSALES WORLD 2005

23 Sep 05

Pharma Sales World 2005 will provide delegates with a unique opportunity to gain critical business information about how Europe’s leading pharma companies are addressing the challenge of improving sales force effectiveness. The conference will highlight the issues of accessibility, emerging customer bases, market changes in the next decade, sales force size and structure, targeting and segmentation, the new breed of representative, data acquisition, training and development, customer relationshi
Hannah Reading

Osteoporosis

23 Sep 05

Fractures resulting from osteoporosis are widely recognised as a major cause of morbidity and mortality in the elderly population. It has been estimated that approximately 310,000 osteoporotic fractures occur annually in the UK, with a consequent cost to the health service of £1.7 billion.
CSF Medical

Exco Group- Win Small Business of the Year 2005

20 Sep 05

On Friday 16th September, before a glittering audience of local business Champions, Exco was awarded the highly acclaimed prize of Small Business of the Year 2005.
Sarah Eadon

U.S. and EU NME/NAS Submissions Hit Five-Year High in 2004

06 Sep 05

The pharmaceutical industry’s new molecular entity (NME) submissions to the U.S. FDA and new active substance (NAS) submissions to the European Medicines Evaluation Agency (EMEA) rose to five-year highs in 2004, according to PAREXEL’s Pharmaceutical R&D Statistical Sourcebook 2005/2006.
http://www.barnettinternational.com

Epilepsy

05 Sep 05

Epilepsy is characterised by a tendency to experience unprovoked seizures and is one of the most common neurological disorders. Over 2% of the population will experience a seizure at some time in their life, and recurrent unprovoked seizures will require treatment in approximately one-in-200 people at any given time. Treatment of epilepsy remains important in helping to reduce the psychological and social sequelae which follow on from uncontrolled seizures.
CSF Medical

Schizophrenia

22 Aug 05

It is often forgotten that until the late 1950s there was no treatment for schizophrenia, or for that matter, any other severe enduring mental illness. The majority of patients admitted to asylum care never left: hence the peak occupancy of 150,000 reported in the UK in 1955. As an interesting comparison, this is twice the current UK prison population.
CSF Medical

Advances in the development of Cav2.2 (N-type) calcium channel blockers as analgesics.

18 Aug 05

According to LeadDiscovery's recent feature report, Pain Therapeutics 2005, about one and a half billion people suffer from moderate to severe chronic pain worldwide, driving the market for analgesics to nearly $23 billion in 2004. Many companies are investing heavily in the development of new pain therapeutics, even more so now with the recent problems to have hit the Cox-II inhibitors. Calcium channel blockers stepped into the spotlight at the end of last year with the FDA approval of Elan's Z
LeadDiscovery

Pancratistatin: A tumor selective apoptosis stimulator

18 Aug 05

Worth an estimated $35 billion in 2003, analysts predict that the sale of oncology therapeutics will grow to $60 billion by 2010. Targeted therapeutics represent one of the most exciting new developments in the field of oncology and include angiogenesis inhibitors; apoptosis stimulators and; signal transduction inhibitors. Apoptosis stimulators lead by Genta's Genesense are particularly appealing. Canadian researchers are focusing on a stimulator of apoptosis known as pancratistatin. This molecu
LeadDiscovery

Simvastatin as a disease modifying immunoregulatory candidate treatment of Parkinson's disease

18 Aug 05

Parkinson's disease drug revenues grew an impressive 17% across the seven major markets to reach $1.7 billion in 2003. Despite the commercial success associated with this therapy area, currently available treatments focus on levodopa which replaces the loss of striatal dopamine, the hall mark of Parkinson's disease, rather than targeting disease progression. The efficacy of levodopa eventually declines in most patients and new therapies with disease modifying activity are urgently required. A gr
LeadDiscovery

The combined use of angiotensin receptor blockers and long-acting calcium channel blockers as an effective approach to hypertension

18 Aug 05

Hypertension continues to represent a highly prevalent clinical problem affecting 190 million people in the 7 major pharmaceutical markets. This therapeutic area is also a highly lucrative field for pharmaceutical companies with sales exceeding $30 billion in 2003. Despite the improved efficacy and tolerability of the angiotensin receptor blocker class led by valsartan, physicians remain frustrated by the lack of efficacy of antihypertensive agents and the current trend is towards the use of com
LeadDiscovery

Histone deacetylase 2 (HDAC2): Modulation of HDAC2 and its implication for chronic obstructive airway diseases (COPD) and cancer.

18 Aug 05

Earlier in 2005, LeadDiscovery published an in depth report on the development of the novel anti-cancer class, the HDAC inhibitors. As this class advances with therapeutic candidates now entering phase II trials, companies are seeking to optimize therapeutic margins by targeting specific isoforms of histone deacetylase that are involved in tumor progression. In a recent NEJM study Prof. Peter Barnes and colleagues demonstrates that the inhibition of HDAC2 could introduce airway risks, possibly e
LeadDiscovery

Dual VEGF- and Erb-receptor inhibition as an improved strategy for treating cancer

18 Aug 05

The overlapping fields of angiogenesis and growth factor biology represent two extensively investigated areas of modern day oncology and the recent success of Avastin, a monoclonal antibody that binds to and neutralizes one such growth factor, VEGF has not only resulted in the introduction of an effective clinical tool for the treatment of cancer but it also helped spark a wave of optimism in the angiogenesis inhibitor arena. As a result companies are evaluating new approaches to target VEGF in
LeadDiscovery

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.